Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPERA trial of PF-00547659 in Crohn's disease
NL-OMON39273Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ontamalimab in Crohn's disease, sponsored by Pfizer. Primary endpoint: CDAI-70 response rate at Week 8 or Week 12. Started Mar 2012; status: active, not recruiting.
02
Drugs
ontamalimab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON39273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39273.